300 research publications using ACD’s RNAscope® Technology

Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, is celebrating a significant milestone. Over 300 peer-reviewed research papers have now been published that feature ACD’s RNAscope technology as a core part of the research methodology, reflecting its facility in advancing the latest biological research in both academia and industry.

1504ACD06Oct ACD’s RNAscope® Technology Achieves 300-publication Milestone

RNA in situ hybridization (ISH) is a valuable tool for studying spatial and cell-specific gene expression, while preserving tissue architecture. ACD’s RNAscope represents a breakthrough advance in RNA ISH, implementing a proprietary signal amplification system to enhance both sensitivity and specificity, producing a high-performance assay that is also quick and easy to use. As awareness has spread of how RNAscope ISH can accelerate a variety of studies, its rise in uptake has translated to a rapid increase in published research. Thus far in 2015, the number of new publications has already exceeded 150, more than the total number of publications from all the previous years combined, signaling acceleration in technology adoption.

Chief Scientific Officer, Dr. Xiao-Jun Ma, commented:

This rapid increase in publications speaks directly to the value of RNAscope technology in many fields of research. Spatially mapped single-cell gene expression data are crucial to understanding the development, structure and function of complex tissues at the molecular and cellular level. However, obtaining such data has been a huge bottleneck due to technical difficulties of traditional RNA ISH methods and the loss of contextual information with grind-and-bind assays. With RNAscope, such data can be generated within weeks from a concept to publication quality images.”

The papers range from basic research in developmental biology, neuroscience, stem cells and ophthalmology, to translational research and diagnostic development of biomarkers in cancer and infectious diseases, in respected journals such as Nature, Science, Cell, New England Journal of Medicine, PNAS, PLoS One, and Clinical Cancer Research.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Advanced Cell Diagnostics. (2019, June 20). 300 research publications using ACD’s RNAscope® Technology. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20151006/300-research-publications-using-ACDs-RNAscope-Technology.aspx.

  • MLA

    Advanced Cell Diagnostics. "300 research publications using ACD’s RNAscope® Technology". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20151006/300-research-publications-using-ACDs-RNAscope-Technology.aspx>.

  • Chicago

    Advanced Cell Diagnostics. "300 research publications using ACD’s RNAscope® Technology". News-Medical. https://www.news-medical.net/news/20151006/300-research-publications-using-ACDs-RNAscope-Technology.aspx. (accessed November 24, 2024).

  • Harvard

    Advanced Cell Diagnostics. 2019. 300 research publications using ACD’s RNAscope® Technology. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20151006/300-research-publications-using-ACDs-RNAscope-Technology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121